Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Bioorg Med Chem. 2014 Jan 3;22(3):1163–1175. doi: 10.1016/j.bmc.2013.12.027

Figure 2.

Figure 2

Structure–activity relationships of various oxyoxalamide derivatives as inhibitors of the human sEH were explored. In order to first investigate whether the substituted oxyoxalamides can be an effective primary pharmacophore to inhibit the target enzyme, various substituents were introduced into the oxyoxalamide function as shown in A (Tables 1 and 2). In addition, in order to see if it can be an effective secondary pharmacophore to improve inhibition and/or solubility of amide- or urea-based inhibitors, the substituted oxyoxalamides with a variety of groups were incorporated to amide and urea inhibitors as seen in B (Tables 3 and 4).